ADAPTIVE BIOTECHNOLOGIES (ADPT) Fundamental Analysis & Valuation

NASDAQ:ADPT • US00650F1093

Current stock price

14.08 USD
-0.73 (-4.93%)
At close:
14.08 USD
0 (0%)
After Hours:

This ADPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ADPT Profitability Analysis

1.1 Basic Checks

  • In the past year ADPT has reported negative net income.
  • ADPT had a negative operating cash flow in the past year.
  • ADPT had negative earnings in each of the past 5 years.
  • In the past 5 years ADPT always reported negative operating cash flow.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • ADPT's Return On Assets of -11.60% is in line compared to the rest of the industry. ADPT outperforms 43.86% of its industry peers.
  • The Return On Equity of ADPT (-27.19%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -11.6%
ROE -27.19%
ROIC N/A
ROA(3y)-25.08%
ROA(5y)-24.21%
ROE(3y)-59.64%
ROE(5y)-51.27%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 74.24%, ADPT belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ADPT has remained more or less at the same level.
  • ADPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5Y-0.76%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ADPT Health Analysis

2.1 Basic Checks

  • ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ADPT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ADPT has more shares outstanding
  • Compared to 1 year ago, ADPT has a worse debt to assets ratio.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ADPT has an Altman-Z score of 1.37. This is a bad value and indicates that ADPT is not financially healthy and even has some risk of bankruptcy.
  • ADPT has a Altman-Z score (1.37) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.58 indicates that ADPT is somewhat dependend on debt financing.
  • ADPT has a worse Debt to Equity ratio (0.58) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z 1.37
ROIC/WACCN/A
WACC11.05%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • ADPT has a Current Ratio of 3.34. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
  • ADPT's Current ratio of 3.34 is fine compared to the rest of the industry. ADPT outperforms 61.40% of its industry peers.
  • A Quick Ratio of 3.23 indicates that ADPT has no problem at all paying its short term obligations.
  • The Quick ratio of ADPT (3.23) is better than 63.16% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.23
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADPT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 63.30% over the past year.
  • ADPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.77%.
  • ADPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.00% yearly.
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.87%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y14.34%
Revenue growth 5Y23%
Sales Q2Q%51.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.58% on average over the next years. This is quite good.
  • ADPT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.37% yearly.
EPS Next Y-23.67%
EPS Next 2Y15.08%
EPS Next 3Y22.98%
EPS Next 5Y14.58%
Revenue Next Year6.68%
Revenue Next 2Y14.42%
Revenue Next 3Y16.2%
Revenue Next 5Y19.37%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. ADPT Valuation Analysis

4.1 Price/Earnings Ratio

  • ADPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • ADPT's earnings are expected to grow with 22.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.08%
EPS Next 3Y22.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADPT Dividend Analysis

5.1 Amount

  • No dividends for ADPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADPT Fundamentals: All Metrics, Ratios and Statistics

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (4/6/2026, 8:19:58 PM)

After market: 14.08 0 (0%)

14.08

-0.73 (-4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)04-29
Inst Owners100.88%
Inst Owner Change0%
Ins Owners2.11%
Ins Owner Change-5.59%
Market Cap2.17B
Revenue(TTM)276.98M
Net Income(TTM)-59.50M
Analysts84.29
Price Target21.27 (51.07%)
Short Float %6.15%
Short Ratio4.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.77%
Min EPS beat(2)51.32%
Max EPS beat(2)140.22%
EPS beat(4)4
Avg EPS beat(4)63.67%
Min EPS beat(4)30.19%
Max EPS beat(4)140.22%
EPS beat(8)8
Avg EPS beat(8)38.23%
EPS beat(12)10
Avg EPS beat(12)26.53%
EPS beat(16)14
Avg EPS beat(16)23.58%
Revenue beat(2)2
Avg Revenue beat(2)30.42%
Min Revenue beat(2)18.33%
Max Revenue beat(2)42.52%
Revenue beat(4)4
Avg Revenue beat(4)24.54%
Min Revenue beat(4)16.85%
Max Revenue beat(4)42.52%
Revenue beat(8)8
Avg Revenue beat(8)15.98%
Revenue beat(12)10
Avg Revenue beat(12)9.51%
Revenue beat(16)12
Avg Revenue beat(16)7.04%
PT rev (1m)0%
PT rev (3m)5.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.93%
EPS NY rev (1m)0%
EPS NY rev (3m)15.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.83
P/FCF N/A
P/OCF N/A
P/B 9.91
P/tB 22.1
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS1.8
BVpS1.42
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.6%
ROE -27.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.24%
FCFM N/A
ROA(3y)-25.08%
ROA(5y)-24.21%
ROE(3y)-59.64%
ROE(5y)-51.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5Y-0.76%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.59%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 3.23
Altman-Z 1.37
F-Score5
WACC11.05%
ROIC/WACCN/A
Cap/Depr(3y)27.91%
Cap/Depr(5y)120.49%
Cap/Sales(3y)3.13%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.87%
EPS Next Y-23.67%
EPS Next 2Y15.08%
EPS Next 3Y22.98%
EPS Next 5Y14.58%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y14.34%
Revenue growth 5Y23%
Sales Q2Q%51.04%
Revenue Next Year6.68%
Revenue Next 2Y14.42%
Revenue Next 3Y16.2%
Revenue Next 5Y19.37%
EBIT growth 1Y63.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.85%
EBIT Next 3Y36.37%
EBIT Next 5Y24.27%
FCF growth 1Y50.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.7%
OCF growth 3YN/A
OCF growth 5YN/A

ADAPTIVE BIOTECHNOLOGIES / ADPT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ADAPTIVE BIOTECHNOLOGIES?

ChartMill assigns a fundamental rating of 3 / 10 to ADPT.


What is the valuation status for ADPT stock?

ChartMill assigns a valuation rating of 1 / 10 to ADAPTIVE BIOTECHNOLOGIES (ADPT). This can be considered as Overvalued.


How profitable is ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?

ADAPTIVE BIOTECHNOLOGIES (ADPT) has a profitability rating of 2 / 10.


What is the financial health of ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?

The financial health rating of ADAPTIVE BIOTECHNOLOGIES (ADPT) is 3 / 10.


What is the expected EPS growth for ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?

The Earnings per Share (EPS) of ADAPTIVE BIOTECHNOLOGIES (ADPT) is expected to decline by -23.67% in the next year.